Nothing Special   »   [go: up one dir, main page]

DE60215649D1 - Zusammensetzungen und verfahren zur behandlung von hyperimmunreaktionen im auge - Google Patents

Zusammensetzungen und verfahren zur behandlung von hyperimmunreaktionen im auge

Info

Publication number
DE60215649D1
DE60215649D1 DE60215649T DE60215649T DE60215649D1 DE 60215649 D1 DE60215649 D1 DE 60215649D1 DE 60215649 T DE60215649 T DE 60215649T DE 60215649 T DE60215649 T DE 60215649T DE 60215649 D1 DE60215649 D1 DE 60215649D1
Authority
DE
Germany
Prior art keywords
eye
compositions
methods
hyperimmune reactions
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60215649T
Other languages
English (en)
Inventor
Simon Skurkovich
Boris Skurkovich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advanced Biotherapy Concepts Inc
Original Assignee
Advanced Biotherapy Concepts Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Biotherapy Concepts Inc filed Critical Advanced Biotherapy Concepts Inc
Application granted granted Critical
Publication of DE60215649D1 publication Critical patent/DE60215649D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
DE60215649T 2001-06-05 2002-06-04 Zusammensetzungen und verfahren zur behandlung von hyperimmunreaktionen im auge Expired - Lifetime DE60215649D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29589501P 2001-06-05 2001-06-05
US09/894,287 US6534059B2 (en) 2001-06-05 2001-06-28 Compositions and methods for treating hyperimmune response in the eye
PCT/US2002/017677 WO2002098460A1 (en) 2001-06-05 2002-06-04 Compositions and methods for treating hyperimmune response in the eye

Publications (1)

Publication Number Publication Date
DE60215649D1 true DE60215649D1 (de) 2006-12-07

Family

ID=26969391

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60215649T Expired - Lifetime DE60215649D1 (de) 2001-06-05 2002-06-04 Zusammensetzungen und verfahren zur behandlung von hyperimmunreaktionen im auge

Country Status (9)

Country Link
US (2) US6534059B2 (de)
EP (1) EP1401496B1 (de)
JP (1) JP2004532885A (de)
AT (1) ATE343398T1 (de)
AU (1) AU2002318175B2 (de)
CA (1) CA2449488C (de)
DE (1) DE60215649D1 (de)
HK (1) HK1063601A1 (de)
WO (1) WO2002098460A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6709655B2 (en) * 2001-02-28 2004-03-23 Instituto Bioclon, S.A. De C.V. Pharmaceutical composition of F(ab1)2 antibody fragments and a process for the preparation thereof
US6861056B2 (en) * 2001-06-05 2005-03-01 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
US6534059B2 (en) * 2001-06-05 2003-03-18 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
US6712976B2 (en) * 2001-09-13 2004-03-30 Abtech Industries, Inc. Dual-action decontamination system
US7335759B2 (en) 2002-12-02 2008-02-26 Universidad Nacional Autónoma de Méxica (UNAM) Recombinant immunogens for the generation of antivenoms to the venom of scorpions of the genus Centruroides
EP1651266B1 (de) * 2003-07-25 2010-03-03 Laboratorios Silanes, S.A. de C.V. Verabreichung von anti-tnf-alpha f(ab')2 antikörper-fragmenten
ES2381203T3 (es) * 2005-01-27 2012-05-24 Novimmune Sa Anticuerpos anti-interferón gamma humanos y métodos de uso de los mismos
WO2006102654A1 (en) * 2005-03-24 2006-09-28 Washington University Reduction of ophthamologic neovascularization
US7381802B2 (en) * 2005-04-15 2008-06-03 Universidad Nacional Autónoma De México (UNAM) Human antibodies that specifically recognize the toxin Cn2 from Centruroides noxius scorpion venom
CN101489569A (zh) * 2006-06-12 2009-07-22 席拉坎有限责任公司 眼表面疾病的局部治疗
CA2734185C (en) * 2008-08-15 2017-02-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for using interferon gamma to absorb fluid from the subretinal space
US11091543B2 (en) 2015-05-07 2021-08-17 Swedish Orphan Biovitrum Ag Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
IL282923B2 (en) 2015-05-07 2023-10-01 Novimmune Sa Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
HU206897B (en) 1985-10-25 1993-01-28 Zymogenetics Inc Process for utilizing bar-1 gen for selecting strange proteins
EP0247091B1 (de) 1985-11-01 1993-09-29 Xoma Corporation Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905400D0 (en) * 1989-03-09 1989-04-19 Jonker Margreet Medicaments
JP3679112B2 (ja) * 1991-10-04 2005-08-03 アメリカ合衆国 細胞接着分子の遮断による眼の炎症の治療
US5888511A (en) 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
DE19535073C1 (de) * 1995-09-21 1997-02-20 Roland Dr Grosmann Verfahren zur künstlichen Inkubation von Hühnereiern
US6861056B2 (en) * 2001-06-05 2005-03-01 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
US6534059B2 (en) * 2001-06-05 2003-03-18 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye

Also Published As

Publication number Publication date
HK1063601A1 (en) 2005-01-07
CA2449488A1 (en) 2002-12-12
EP1401496A4 (de) 2005-08-31
ATE343398T1 (de) 2006-11-15
EP1401496B1 (de) 2006-10-25
EP1401496A1 (de) 2004-03-31
US7232568B2 (en) 2007-06-19
AU2002318175B2 (en) 2006-01-05
JP2004532885A (ja) 2004-10-28
CA2449488C (en) 2010-02-09
WO2002098460A1 (en) 2002-12-12
US20030224005A1 (en) 2003-12-04
US6534059B2 (en) 2003-03-18
US20020182212A1 (en) 2002-12-05

Similar Documents

Publication Publication Date Title
ATE343398T1 (de) Zusammensetzungen und verfahren zur behandlung von hyperimmunreaktionen im auge
IL148079A0 (en) Human ctla-4 antibodies and compositions containing the same
IL169152A0 (en) Antibodies against pd-1 and uses therefor
DE69935133D1 (de) Antagoniste zur behandlung von cd11/cd18 adhäsionsrezeptor-vermittelten krankheiten
DE60005953D1 (de) Stapelbare statische mischelemente
WO2005016962A3 (en) Compositions and methods for the treatment of immune related diseases
BG110703A (en) PHARMACEUTICAL COMPOSITION, INCLUDING HUMAN ANTIBODIES CONNECTING HUMAN TNF ALPHA AND HIS APPLICATION
ATE448775T1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
WO2005059106A3 (en) Interferon alpha antibodies and their uses
DE60335552D1 (de) Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen
ATE202706T1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
BR0008688A (pt) Antagonistas de il-18 recombinantes utilizáveis no tratamento de distúrbios mediados por il-18
EP1064308A4 (de) Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
DE69325393D1 (de) Pharmazeutische zusammensetzungen und verfahren unter verwendung von isobutyramid zur behandlung von betaglobinerkrankungen
DE60034871D1 (de) Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust
DE602004021847D1 (de) Verfahren zur prävention und behandlung von diabetes mit neurturin
DE60313434D1 (de) Verfahren und zusammensetzungen zur behandlung von hyperproliferativen zuständen
DE60035693D1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
ATE196083T1 (de) Verwendung von ferrioxamin-b zur behandlung septischen schocks
ATE423110T1 (de) Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
WO2004083382A3 (en) Compositions and methods for treating hyperimmune response in the eye
DE60024997D1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
ATE213233T1 (de) Substituierte caprolactame und deren derivate verwendbar zur behandlung der hiv-krankheit
ATE494903T1 (de) Verwendung von slurp-1 zur behandlung von krankheiten, die durch störungen der acetylcholinerezeptoren ausgelöst werden

Legal Events

Date Code Title Description
8332 No legal effect for de